Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis.

Kivitz, Alan; Baret-Cormel, Lydie; van Hoogstraten, Hubert; Wang, Sheldon; Parrino, Janie; Xu, Christine; Stanislav, Marina

Kivitz, Alan; Baret-Cormel, Lydie; van Hoogstraten, Hubert; Wang, Sheldon; Parrino, Janie; Xu, Christine; Stanislav, Marina.

Afiliação

Kivitz A; Altoona Center for Clinical Research, Duncansville, PA, USA. ajkivitz@yahoo.com.
Baret-Cormel L; Sanofi, Paris, France.
van Hoogstraten H; Sanofi Genzyme, Bridgewater, NJ, USA.
Wang S; Sanofi Genzyme, Bridgewater, NJ, USA.
Parrino J; Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.
Xu C; Sanofi Genzyme, Bridgewater, NJ, USA.
Stanislav M; V.A. Nassonova Research Rheumatology Institute, Moscow, Russia.

Rheumatol Ther ; 5(1): 231-242, 2018 Jun.

Article em En | MEDLINE | ID: mdl-29209946

Palavras-chave

Autoinjector; IL-6; IL-6Rα; Patient preference; Pen; Prefilled syringe; Rheumatoid arthritis; Sarilumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Rheumatol Ther Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google